Published: 30 January 2013Financial Investment & StockPartnership News & Expansion

Oslo, Norway, January 30, 2013: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces that its strategic partner Ipsen has announced the 4Q 2012 and full year 2012 sales results for Hexvix®, the flagship brand to aid in diagnosing bladder cancer. The announcement from Ipsen is available on

Photocure will present its 4Q2012 and full year 2012 results on February 28, 2013.

Ipsen, a leader in uro-oncology, is Photocure's strategic partner for commercializing Hexvix and is responsible for marketing and selling Hexvix worldwide, excluding the US and Nordic region. Ipsen has a strong and well established uro-oncology franchise and commercializes Hexvix through its dedicated sales force. In November 2011 Ipsen initiated commercialization of Hexvix in Germany and Italy and became fully operational in the remainder of the markets in their territory during the 1H 2012.

For further information, please contact:
President & CEO Kjetil Hestdal
Tel: + 47 913 19 535, Email:

CFO Erik Dahl
Tel: +47 50 55 000, Email:

M: Communications
Mary Clark, Amber Bielecka, Hollie Vile
Tel: +44 207920 2361, Email:

About Photocure ASA
Photocure, headquartered in Oslo Norway, is a specialty pharmaceutical company and world leader in photodynamic technology. Based on our unique proprietary Photocure Technology(TM) platform, Photocure develops and commercializes highly selective and effective solutions within disease areas with high unmet medical need, such as bladder cancer, HPV and precancerous cervical lesions, colorectal cancer and skin conditions. Our aim is to provide solutions which can improve health outcomes for patients worldwide. Photocure is listed on the Oslo Stock Exchange (OSE: PHO). Information about Photocure is available at

All trademarks mentioned in this release are protected by law and registered trademarks of Photocure.

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

News and events